[New derivatives of 10,11-dihydro-5H-dibenz[b,f]azepine with antiarrhythmic action].
After an introduction about the importance of the 10, 11-Dihydro-5H-dibenz[b,f]azepine system for the drug research and according to experiences about the change of pharmacodynamic effects in the field of the phenothiazine bases by dialkylaminoacyl substitution in the following report some new 3-carbalkoxyamino-5-omega-aminoacyl-10,11-dihydro-5H-dibenz[b,f]++ +azepines and their intermediates for synthesis are described. In result of pharmacological investigations which showed antiarrhythmic activities the substance 3-carbethoxyamino-5-dimethylaminoacetyl-10,11-Dihydro-5H-dib enz[b, f]azepine X HCl (GS 015, AWD 19-166, Bonnecor) was selected for clinical tests. For studying the biotransformation of this substance the expected main metabolites were prepared by chemical synthesis.
D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000138:chemical synthesis* / Q000378:metabolism; D001711:Biotransformation; D055598:Chemical Phenomena; D002621:Chemistry; D003984:Dibenzazepines / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology; D010084:Oxidation-Reduction
D000889:Anti-Arrhythmia Agents; D003984:Dibenzazepines
Neue Derivate des 10,11-Dihydro-5H-dibenz[b,f]azepins mit antiarrhythmischer Wirkung.